All Updates

All Updates

icon
Filter
Partnerships
Hoth Therapeutics partners with Wise International for AI-aided drug discovery
AI Drug Discovery
Jun 10, 2024
This week:
Robinhood launches joint investment accounts
Retail Trading Infrastructure
Jul 25, 2024
Partnerships
eToro partners with London Stock Exchange to expand UK stock offerings
Retail Trading Infrastructure
Jul 25, 2024
Funding
StorMagic secures funding from Palatine Growth Credit Fund
Edge Computing
Jul 25, 2024
Funding
Archera raises USD 17 million in Series B funding for product development and recruitment
Cloud Optimization Tools
Jul 25, 2024
Funding
Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100
Precision Medicine
Jul 25, 2024
Partnerships
Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases
Precision Medicine
Jul 25, 2024
Product updates
USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products
Next-gen Satellites
Jul 25, 2024
Industry news
Sweden issues study on Gripen fighter jet’s satellite launch capability
Next-gen Satellites
Jul 25, 2024
Product updates
Regulation/policy
Terran Orbital receives certification for new manufacturing facility to begin production
Next-gen Satellites
Jul 25, 2024
Partnerships
Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft
Passenger eVTOL Aircraft
Jul 25, 2024
AI Drug Discovery

AI Drug Discovery

Jun 10, 2024

Hoth Therapeutics partners with Wise International for AI-aided drug discovery

Partnerships

  • AI-aided drug developer company Hoth Therapeutics has entered a strategic partnership with IT and software solutions provider Wise Systems International to leverage AI-based technology for drug discovery.

  • The collaboration includes Hoth’s access to NVIDIA's BioNeMo AI platform, which can help build and integrate GenAI applications across the entire drug discovery pipeline. With Wise's help, the company aims to further its ongoing pipeline and discover novel therapeutics.

  • Hoth Therapeutics is a biopharmaceutical company that develops therapies for unmet medical needs. The company's pipeline includes HT-001, a topical treatment in Phase II clinical trials for rash and skin disorders associated with cancer therapies, HT-KIT for mast-cell derived cancers and anaphylaxis, HT-TBI for traumatic brain injury and ischemic stroke, and HT-ALZ for Alzheimer’s disease.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.